$3.45 0.01 (+0.29%)
11/6/2009 4:00 PM

ArQule, Inc. (ARQL)

CAPS Rating: 2 out of 5

A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.

Current Price $3.45 Mkt Cap $154.13M
Open $0.00 P/E Ratio 0.00
Prev. Close $3.44 Div. (Yield) N/A (N/A)
Daily Range $3.40 - $3.52 Volume 129,242
52-Wk Range $2.11 - $6.38 Avg. Daily Vol. 242,000

ARQL News and Commentary

Caps

How do you think ARQL will perform vs the S&P 500?

Add Stock to Watchlist

All Members

127 Outperform
20 Underperform
 

All-Star Members

34 Outperform
13 Underperform
 

Wall Street

11 Outperform
0 Underperform
 

Top ARQL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

NetscribeHealthC (20.20)
Submitted March 12, 2007

ArQule is developing a portfolio of proprietary small molecule drugs to treat cancer. The company’s technology platform includes the Activated Checkpoint Therapy (ACT) program, which seeks to harness the cell's natural defense mechanism against… More

0 Comments | Reply | Report this Post

pajeth (< 20)
Submitted February 19, 2007

Carefully watching this stock, hoping for some positive news.

0 Comments | Reply | Report this Post
ARQL VS S&P 500 (SPY)

Fools bullish on ARQL are also bullish on:

Fools bearish on ARQL are also bearish on:

Recent Community Commentary

Read the most recent pitches from members about ARQL.

Recs

0
Member Avatar CaptainFiveBaggr (99.82) Submitted: 12/19/2008 11:44:43 AM : Underperform Start Price: $4.51 ARQL Score: +45.71

My general feeling is the market will pick up faster than people think. I hate the oft quoted- "well, it is going to get worse before it gets better" Dumbest thing to say of all time. Its a cowardly escape from assessing WHEN it might turn around. My feeling is sooner than everyone else expects it too. However. This company will most likely go out of business in 2-4 years. Good luck

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar wakoma (61.08) Submitted: 9/29/2008 7:46:43 AM : Outperform Start Price: $3.15 ARQL Score: +17.30

Bought based on feedback from a couple of friends in the oncology industry. Small position. yrs away from knowing the outcome. Some smart money likes what they see. Who knows. Pretty much dead money for the near term

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar Dapperatom (< 20) Submitted: 5/14/2008 1:54:31 PM : Outperform Start Price: $4.23 ARQL Score: +3.35

I like the below $10 price and its potential for a good return.

Report this Post 0 Comments | Reply | Permalink
View All 20 Pitches »

Leaderboard

Find the members with the highest scoring picks in ARQL.

Score Leader

richsimpson

richsimpson (97.72) Score: +114.09

The Score Leader is the member with the highest score across all their picks in ARQL.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
WeatherMachine 82.45 7/13/2009 Underperform 5Y $5.81 -40.62% +21.89% +62.51
rockfishcc8 < 20 7/15/2009 Underperform 3M $6.02 -42.69% +15.85% +58.54
CVMp 87.88 7/29/2009 Underperform 5Y $6.00 -42.50% +10.77% +53.27
Hero4All 94.76 6/12/2009 Underperform 5Y $5.58 -38.17% +14.70% +52.88
TheSkyIsFalling 99.68 7/17/2009 Underperform 5Y $5.60 -38.39% +14.33% +52.73
Monica109 96.83 4/2/2009 Underperform 5Y $4.41 -21.77% +30.29% +52.06
columbia1 30.25 6/8/2009 Underperform 5Y $5.42 -36.35% +15.35% +51.70
anticitradeshort 25.36 4/20/2009 Underperform NS $4.37 -21.05% +26.54% +47.60
laugef 98.18 10/10/2008 Outperform 5Y $1.95 +76.92% +29.55% +47.38
CaptainFiveBaggr 99.82 12/19/2008 Underperform 3Y $4.51 -23.50% +22.21% +45.71 1 Comment
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackUBS 86.41 10/14/2009 Outperform NS $4.35 -20.69% -0.24% -20.45
TrackUBS 86.41 7/16/2009 Underperform NS $5.38 -19.14% +15.38% +34.52 10/13/2009 @ $4.35
TrackOppenheimer 26.63 12/1/2008 Outperform NS $3.29 +4.86% +25.60% -20.74
TrackBofASec 93.50 9/3/2008 Outperform NS $3.44 +0.29% -13.58% +13.87
TrackUBS 86.41 1/29/2008 Outperform NS $5.18 -17.37% -38.52% +21.15 4/3/2009 @ $4.28
TrackBofASec 93.50 12/4/2007 Outperform NS $6.62 -29.31% -4.69% -24.61 1/9/2008 @ $4.68
TrackEveillard 89.92 9/30/2007 Outperform NS $7.13 -51.61% -26.44% -25.18 1 Comment
TrackLazardCapit < 20 9/14/2007 Outperform NS $7.68 -55.08% -24.00% -31.08
TrackNeedham < 20 6/1/2007 Outperform NS $9.37 -63.18% -26.49% -36.69
TrackCantorFitz 25.13 5/22/2007 Outperform NS $9.46 -63.53% -25.83% -37.70
TrackStanfordRes 80.42 5/3/2007 Outperform NS $9.11 -62.13% -24.62% -37.51
TrackFortisBank 86.13 4/30/2007 Outperform NS $9.28 -62.82% -24.30% -38.52
TrackLeerinkSwan 84.26 4/4/2007 Outperform NS $7.74 -55.43% -21.16% -34.27
TrackWRHambrecht 59.03 3/8/2007 Outperform NS $6.52 -47.09% -19.40% -27.68

Featured Broker Partners